Prolonged paradoxical reaction to anti-tuberculous treatment after discontinuation of TNF-alpha- blocker therapy with adalimumab. Rare clinical documentation

In the past decades, tumor necrosis factor alpha (TNF-a) antagonist has been a milestone in the treatment of many chronic inflammatory diseases. TNF antagonist can increase patients’ susceptibility to many different kinds of infections especially those requiring granuloma formations despite regular...

Descripción completa

Detalles Bibliográficos
Autores principales: Falkenstern-Ge, Roger Fei, Husemann, Kim, Kohlhäufl, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5152954/
https://www.ncbi.nlm.nih.gov/pubmed/28352675
http://dx.doi.org/10.1515/med-2015-0009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5152954/
https://www.ncbi.nlm.nih.gov/pubmed/28352675
http://dx.doi.org/10.1515/med-2015-0009

Ejemplares similares